FDA setback for Sanofi’s Tolebrutinib in progressive MS

Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity

IRLAB launches Phase Ib Trial of IRL757 for Parkinson’s patients with Apathy

The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain

Sanofi flags delay in FDA review of Tolebrutinib for progressive multiple sclerosis

Roche reports breakthrough phase III results for investigational multiple sclerosis drug

Fenebrutinib targets cells in the immune system known as B cells and microglia

Johnson & Johnson gets FDA nod for new depression treatment

This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials

Novo Nordisk's oral semaglutide gets EU approval for heart related treatment of type 2 diabet

EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke

GST rejig may impact competitiveness of medical devices: AiMeD

AiMeD noted that proposed GST changes—to either 5% or 18%—both present significant risks requiring carefully nuanced consideration

IICP and Indegene partner to enable more inclusive society

IICP is a registered charitable society working in the disability sector since 1974

Emcure Pharmaceuticals teams up with MS Dhoni to bat for stroke awareness

Emcure and Dhoni, through a video, urge everyone to be aware about symptoms of stroke and educate at least one person for identification of stroke and spread its awareness

Indian Stroke Association launches the Bangalore chapter of ‘Mission Brain Attack’

Strokes are affecting approximately 1.8 million people annually